LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre

Bone Marrow Transplantation

Volumn 39, Issue 1, 2007, Pages 41-47

  Perz, J B ^a   Giles, C ^a   Szydlo, R ^a   O'Shea, D ^a   Sanz, J ^a   Chaidos, A ^a   Wagner, S ^a   Davis, J ^a   Loaiza, S ^a   Marin, D ^a   Apperley, J ^a   Olavarria, E ^a   Rahemtulla, A ^a   Lampert, I ^b   Naresh, K ^b   Samson, D ^a   MacDonald, D ^a   Kanfer, E J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; LOMUSTINE; MESNA; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG FATALITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SALVAGE THERAPY; SEPSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33845517981     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705544     Document Type: Article

References (30)

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. German Hodgkin's Lymphoma Study Group; lymphoma working party of the European group for blood and marrow transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed or resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. Carella A, Carlier P, Congiu A, Occhini D, Meloni G, Anselmo AP et al. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report. Leukemia 1991; 5 (Suppl 1): 68-71.
4. Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymph 1996; 21: 63-70.
5. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98-106.
6. Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999; 23: 1131-1138.
7. Taylor PR, Jackson GH, Lennard AL, Lucraft H, Proctor SJ. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/ etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group. Br J Cancer 1993; 67: 383-387.
8. Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: Analysis of efficacy, toxicity and prognostic factors. Leuk Lymph 2004; 45: 2253-2259.
9. Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R et al. Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation based regimen. Bone Marrow Transplant 2003; 32: 279-285.
10. Stewart DA, Guo D, Gluck S, Morris D, Chaudhry A, deMetz C et al. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000; 26: 383-388.
11. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
12. Czyz J, Dziadziuszko R, Knopinska-Posluszny W, Hellmann A, Kachel L, Holowiecki J et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: A study of 341 patients. Ann Oncol 2004; 15: 1222-1230.
13. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 1015-1023.
14. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J et al. Treatment for primary refractory Hodgkin's disease: A comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225-1229.
15. Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665-672.
16. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
17. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM et al. The International Prognostic Factor Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13: 1370-1377.
18. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
19. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-230.
20. Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J et al. Genetic susceptibility to Hodgkin's disease and secondary neoplasia: FISH analysis reveals patients at high risk of developing secondary neoplasia. Ann Oncol 2002; 13 (Suppl 1): 40-43.
21. Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K et al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autlogous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymph 2001; 40: 499-509.
22. Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber Met al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116-123.
23. Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A, German Hodgkin's Lymphoma Study Group (GHSG). A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol 2002; 81: 424-429.
24. Schmitz N, Sureda A. The role of allogeneic stem-cell transplantation in Hodgkin's disease. Eur J Haematol Suppl 2005; 66: 146-149.
25. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23: 4669-4678.
26. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207-3215.
27. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310-314.
28. Sevilla J, Rodriguez A, Hernandez-Maraver D, de Bustos G, Aguado J, Ojeda E et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell trasnplantation. Ann Hematol 2002; 81: 11-15.
29. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-1478.
30. Oddou S, Vey N, Viens P, Bardou VJ, Faucher C, Stoppa AM et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: A report of six cases in a cohort of 171 patients from a single institution. Leuk Lymph 1998; 31: 187-194.